Meihua International Medical Technologies Co., Ltd. (MHUA) AI Stock Analysis

• Market Cap: $12.23M
• Dividend Yield: N/A
• Average Volume (3M): 157.40K
• Price to Earnings (P/E): 1.1
• Beta (1Y): 1.23
• Revenue Growth: -0.19%
• EPS Growth: -18.41%
• Country: US
• Employees: 619
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.21
• Shares Outstanding: 31,904,469
• 10 Day Avg. Volume: 136,196
• 30 Day Avg. Volume: 157,401
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.07
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $0.50
• Price Target Upside: 25.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: $0.50 ▲(25.00% Upside)

The overall stock score is primarily driven by solid financial performance and a very attractive valuation, suggesting potential undervaluation. However, technical indicators show a lack of momentum, which tempers the overall score.

Meihua International Medical Technologies Co., Ltd. Business Overview & Revenue Model

Company Description

Meihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles. It also distributes disposable medical devices sourced from other manufacturers to customers in China. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.

How the Company Makes Money

Meihua International Medical Technologies Co., Ltd. generates revenue through the sale of its medical products to healthcare institutions and distributors. Its key revenue streams include direct sales to hospitals and clinics, as well as partnerships with medical supply distributors who help expand its market reach. The company benefits from a strong network of distribution channels that facilitate the delivery of its products to a wide range of customers. Additionally, Meihua may engage in strategic collaborations with other healthcare companies to enhance its product offerings and market presence, thereby contributing to its earnings.

Meihua International Medical Technologies Co., Ltd. Financial Statement Overview

Summary

Meihua International Medical Technologies Co., Ltd. demonstrates solid financial health with stable revenue and robust operating performance. While leverage is low, enhancing financial resilience, the company faces challenges in maintaining consistent free cash flow.

Income Statement

The company has demonstrated consistent revenue generation with slight fluctuations. Gross profit margins remain stable, indicating efficient production or service delivery. However, net profit margins have declined, suggesting increased costs or lower efficiency in managing expenses. The EBIT and EBITDA margins are robust, reflecting strong operating performance.

Balance Sheet

The balance sheet shows a strong equity position with a favorable debt-to-equity ratio, indicating low leverage and financial stability. The return on equity has been positive, suggesting effective use of shareholder funds. However, the equity ratio has seen minor variations, reflecting changes in asset management.

Cash Flow

The cash flow statement reveals a significant improvement in operating cash flows in recent years, enhancing liquidity. Despite this, free cash flow has been volatile, occasionally negative, indicating challenges in managing capital expenditures and cash generation relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	96.91M	97.10M	103.35M	104.04M	89.06M
Gross Profit	33.30M	33.10M	38.10M	39.81M	37.16M
EBITDA	15.70M	15.77M	16.12M	26.88M	23.99M
Net Income	10.84M	11.63M	6.24M	20.95M	19.05M
Balance Sheet
Total Assets	186.24M	171.92M	163.58M	136.86M	106.05M
Cash, Cash Equivalents and Short-Term Investments	15.96M	16.93M	26.74M	8.15M	7.19M
Total Debt	7.95M	7.33M	6.81M	5.18M	3.22M
Total Liabilities	27.26M	25.08M	24.90M	30.05M	21.31M
Stockholders Equity	158.98M	146.33M	138.12M	106.81M	84.74M
Cash Flow
Free Cash Flow	14.50M	-2.41M	-11.86M	-904.89K	-10.79M
Operating Cash Flow	14.64M	2.28M	-9.16M	-54.66K	5.33M
Investing Cash Flow	-20.42M	-12.46M	-8.62M	-833.82K	-16.09M
Financing Cash Flow	6.21M	706.13K	37.25M	1.86M	1.71M

Meihua International Medical Technologies Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MHUA, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.41, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.65 is Neutral, neither overbought nor oversold. The STOCH value of 41.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MHUA.

Meihua International Medical Technologies Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	67 Neutral	$12.23M	1.11	7.10%	―	-0.19%	-18.41%
HBIO	55 Neutral	$23.56M	―	-138.36%	―	-12.24%	-427.45%
RVP	52 Neutral	$23.81M	―	-10.80%	―	-0.24%	50.45%
Sector *	50 Neutral	AU$2.62B	3.11	5.87%	2.65%	36.94%	13.62%
EKSO	45 Neutral	$8.46M	―	-96.44%	―	-19.32%	44.73%
POAI	39 Underperform	$9.29M	―	-708.73%	―	-38.79%	58.27%
STSS	―	$5.09M	―	-6.65%	―	―	―